196 related articles for article (PubMed ID: 29491083)
1. Characterization and Management of Borderline Ovarian Tumors - Results of a Retrospective, Single-center Study of Patients Treated at the Department of Gynecology and Obstetrics of the University Medicine Greifswald.
Koensgen D; Weiss M; Assmann K; Brucker SY; Wallwiener D; Stope MB; Mustea A
Anticancer Res; 2018 Mar; 38(3):1539-1545. PubMed ID: 29491083
[TBL] [Abstract][Full Text] [Related]
2. Retrospective evaluation of borderline ovarian tumors: single center experience of 183 cases.
Gungor T; Cetinkaya N; Yalcin H; Ozdal B; Ozgu E; Baser E; Uygur D; Caglar M; Sirvan L; Erkaya S
Arch Gynecol Obstet; 2015 Jan; 291(1):123-30. PubMed ID: 25047273
[TBL] [Abstract][Full Text] [Related]
3. Assessing the risk of clinical and pathologic factors for relapse of borderline ovarian tumours.
Chang C; Chen J; Chen WA; Ho SP; Liou WS; Chiang AJ
J Obstet Gynaecol; 2017 Feb; 37(2):233-237. PubMed ID: 27922289
[TBL] [Abstract][Full Text] [Related]
4. Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD.
Chekerov R; Braicu I; Castillo-Tong DC; Richter R; Cadron I; Mahner S; Woelber L; Marth C; Van Gorp T; Speiser P; Zeillinger R; Vergote I; Sehouli J
Int J Gynecol Cancer; 2013 Feb; 23(2):268-75. PubMed ID: 23358178
[TBL] [Abstract][Full Text] [Related]
5. Borderline Ovarian Tumors: Fifteen Years' Experience at a Scottish Tertiary Cancer Center.
May J; Skorupskaite K; Congiu M; Ghaoui N; Walker GA; Fegan S; Martin CW; O'Donnell RL
Int J Gynecol Cancer; 2018 Nov; 28(9):1683-1691. PubMed ID: 30365457
[TBL] [Abstract][Full Text] [Related]
6. Management of Borderline ovarian tumors (BOT): results of a retrospective, single center study in Switzerland.
Kipp B; Vidal A; Lenick D; Christmann-Schmid C
J Ovarian Res; 2023 Jan; 16(1):20. PubMed ID: 36691070
[TBL] [Abstract][Full Text] [Related]
7. Borderline epithelial ovarian tumors: a single center experience.
Numanoglu C; Ulker V; Kuru O; Akbayir O; Sakinci M; Akyol A
Eur J Gynaecol Oncol; 2014; 35(6):692-5. PubMed ID: 25556277
[TBL] [Abstract][Full Text] [Related]
8. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent.
Silva EG; Gershenson DM; Malpica A; Deavers M
Am J Surg Pathol; 2006 Nov; 30(11):1367-71. PubMed ID: 17063075
[TBL] [Abstract][Full Text] [Related]
9. [Clinical characteristics of borderline ovarian tumors and stage I epithelial ovarian cancer: an analysis of 143 cases].
Zhao Y; Wang Y; Shen Dh; Song Rn; Xu Q; Li Y; Cui H; Tang J; Wei Lh
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Feb; 43(1):123-8. PubMed ID: 21321635
[TBL] [Abstract][Full Text] [Related]
10. Comparison of early-stage primary serous fallopian tube carcinomas and equivalent stage serous epithelial ovarian carcinomas.
Horng HC; Lai CR; Chang WH; Wen KC; Chen YJ; Juang CM; Yen MS; Wang PH
Taiwan J Obstet Gynecol; 2014 Dec; 53(4):547-51. PubMed ID: 25510699
[TBL] [Abstract][Full Text] [Related]
11. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Epidemiology and Risk Factors of Relapse, Follow-up and Interest of a Completion Surgery].
Margueritte F; Sallee C; Lacorre A; Gauroy E; Larouzee E; Chereau E; De La Motte Rouge T; Koskas M; Gauthier T
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):248-259. PubMed ID: 32004784
[TBL] [Abstract][Full Text] [Related]
12. Epithelial ovarian tumors of borderline malignancy.
Chao TM; Yen MS; Chao KC; Ng HT
Zhonghua Yi Xue Za Zhi (Taipei); 1996 Aug; 58(2):97-102. PubMed ID: 8915111
[TBL] [Abstract][Full Text] [Related]
13. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
14. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Short Text].
Bourdel N; Huchon C; Cendos AW; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chéreau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; Mathieu D'argent E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):223-235. PubMed ID: 32004780
[TBL] [Abstract][Full Text] [Related]
15. Oncologic outcome after recurrence in patients with stage I epithelial ovarian cancer: are clear-cell and mucinous histological types a different entities?
Kajiyama H; Mizuno M; Shibata K; Umezu T; Suzuki S; Yamamoto E; Mitsui H; Sekiya R; Niimi K; Kawai M; Nagasaka T; Kikkawa F
Eur J Obstet Gynecol Reprod Biol; 2014 Oct; 181():305-10. PubMed ID: 25203309
[TBL] [Abstract][Full Text] [Related]
16. Borderline ovarian tumors: French guidelines from the CNGOF. Part 1. Epidemiology, biopathology, imaging and biomarkers.
Huchon C; Bourdel N; Abdel Wahab C; Azaïs H; Bendifallah S; Bolze PA; Brun JL; Canlorbe G; Chauvet P; Chereau E; Courbiere B; De La Motte Rouge T; Devouassoux-Shisheboran M; Eymerit-Morin C; Fauvet R; Gauroy E; Gauthier T; Grynberg M; Koskas M; Larouzee E; Lecointre L; Levêque J; Margueritte F; Mathieu D'argent E; Nyangoh-Timoh K; Ouldamer L; Raad J; Raimond E; Ramanah R; Rolland L; Rousset P; Rousset-Jablonski C; Thomassin-Naggara I; Uzan C; Zilliox M; Daraï E
J Gynecol Obstet Hum Reprod; 2021 Jan; 50(1):101965. PubMed ID: 33160106
[TBL] [Abstract][Full Text] [Related]
17. Patterns of recurrence and role of pelvic radiotherapy in ovarian clear cell adenocarcinoma.
Macrie BD; Strauss JB; Helenowski IB; Rademaker A; Schink JC; Lurain JR; Small W
Int J Gynecol Cancer; 2014 Nov; 24(9):1597-602. PubMed ID: 25275661
[TBL] [Abstract][Full Text] [Related]
18. Fertility-sparing surgery for young patients with borderline ovarian tumors (BOTs): single institution experience.
Chen RF; Li J; Zhu TT; Yu HL; Lu X
J Ovarian Res; 2016 Mar; 9():16. PubMed ID: 26988551
[TBL] [Abstract][Full Text] [Related]
19. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma.
Kennedy AW; Hart WR
Cancer; 1996 Jul; 78(2):278-86. PubMed ID: 8674004
[TBL] [Abstract][Full Text] [Related]
20. Clinical Features and Management of Women with Borderline Ovarian Tumors in a Single Center in Brazil.
Yoshida A; Tavares BVG; Sarian LO; Andrade LALÂ; Derchain SF
Rev Bras Ginecol Obstet; 2019 Mar; 41(3):176-182. PubMed ID: 30991432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
